Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T15:42:41.329Z.
Calculation as of: 2026-10-06T15:42:41.329Z.
Quote observation: 2026-10-06T15:40:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5a8aae8e93f82a899e51ff603ce0499f2ee8a4244ac8b174beef8711f00adb15
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$52.78M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$52.61M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Spectral AI, Inc. (MDAI) | $54.74M | N/A | N/A | N/A | N/A |
| Aldeyra The (ALDX)vs › | $54.53M | N/A | N/A | N/A | N/A |
| ImageneBio Inc (IMA)vs › | $53.80M | N/A | N/A | N/A | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.98M | N/A | N/A | N/A | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.98M | N/A | N/A | N/A | N/A |
| NOMAD Power Solutions, Inc. (NMAD)vs › | $52.78M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.98M | N/A | N/A | N/A | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $52.61M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $50.28M | 2.55 | 2.45 | 5.29 | 4.64 |
| MiNK Therapeutics, Inc. (INKT)vs › | $60.58M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
